Abstract
Anorexia nervosa (AN) is a severe eating disorder characterized by abnormal restrictive feeding and a dangerously low body-mass index. It has one of the highest mortality rates of any psychiatric disorder, yet no approved pharmacological treatments exist. Recent genomic data suggests that AN should be reconceptualized as a metabo-psychiatric disorder. This review examines how animal models, particularly the activity-based anorexia (ABA) paradigm, are essential for identifying the biological mechanisms underlying this condition and developing effective treatments.
Introduction: Rethinking Anorexia Nervosa
For decades, Anorexia nervosa was viewed primarily through a sociocultural lens, focusing on the "drive for thinness." However, clinical outcomes remain poor, with relapse rates as high as 52%. A landmark 2019 Genome-Wide Association Study (GWAS) provided a paradigm shift, revealing that the genetic architecture of AN is significantly correlated with metabolic traits—such as insulin sensitivity and lipid levels—in addition to psychiatric ones. This necessitates a "metabo-psychiatric" framework that integrates metabolic dysfunction with core behavioral symptoms.
The Activity-Based Anorexia (ABA) Paradigm
The primary tool for studying these interactions is the Activity-Based Anorexia (ABA) model. In this setup, rodents are given restricted access to food but unlimited access to a running wheel. This creates a behavioral paradox: instead of conserving energy, the animals increase wheel running while further reducing voluntary food intake. This leads to rapid weight loss and mimics the compulsive exercise seen in human patients. Modern "circuit-dissecting" techniques, such as chemogenetics and fiber photometry, allow researchers to observe and manipulate the specific neurons driving this maladaptive behavior in real-time.
Neural Circuits and Metabolic Signaling
Research has identified several critical neural hubs that link energy balance with reward.
- Hypothalamic Hubs: AgRP (Agouti-related protein) neurons in the arcuate nucleus usually drive eating, but their activity drops when running starts in the ABA model. Manipulating these neurons can significantly alter survival rates and fuel mobilization.
- The Dopamine-Metabolism Link: The Nucleus Accumbens (NAc) is a key site where reward and metabolism intersect. Overexpressing Dopamine D2 receptors in the NAc of female mice causes rapid weight loss and glucose intolerance, suggesting that striatal dopamine directly interferes with peripheral metabolic processes.
Biological Drivers: From Genetics to the Gut
The review highlights several specific biological factors that contribute to the AN phenotype:
- Sex Differences: The ABA model successfully reflects the human clinical profile, where females show greater vulnerability to the development of the disorder than males.
- Genetic Loci: GWAS identified loci like CADM1 and FOXP1 expressed in the hypothalamus, providing targets for new genetic mouse models.
- SIRT1 Regulation: Brain-specific knockout of the metabolic regulator SIRT1 protects mice from ABA, while its overexpression promotes hyperactivity and weight loss.
- The Gut-Brain Axis: Transplanting gut microbiota from human AN patients into germ-free mice results in reduced weight gain and increased anxiety, indicating the microbiome is a functional driver of the disease, not just a side effect of starvation.
Future Directions
While animal models cannot capture subjective diagnostic criteria like "body image disturbance," they are vital for mapping the metabo-psychiatric landscape. Future research must focus on fine-mapping human GWAS loci in rodent models and exploring how metabolic signals like ghrelin alter the dopamine reward response to exercise. Identifying specific receptors that drive the ABA phenotype is the first step toward discovering pharmacological treatments that can stabilize both the mind and the metabolism of AN patients.
Summary updated